Skip to content

Advertisement

  • Research
  • Open Access
  • Open Peer Review

Clinical drug trials in general practice: a 10-year overview of protocols

  • 1Email author,
  • 1,
  • 1 and
  • 1
Trials201314:162

https://doi.org/10.1186/1745-6215-14-162

  • Received: 5 October 2012
  • Accepted: 13 May 2013
  • Published:
Open Peer Review reports

Abstract

Background

Drugs predominantly prescribed in general practice should ideally be tested in that setting; however, little is known about drug trials in general practice. Our aim was to describe drug trials in Norwegian general practice over the period of a decade.

Methods

The present work concerns a 10-year retrospective study of protocols submitted to the Norwegian national medicines agency (1998 to 2007) identifying all studies involving general practitioners (GPs) as clinical investigator(s). We analyzed the number of trials, drug company involvement, patients, participating doctors, payment, medications tested and main diagnostic criteria for inclusion. We also analyzed one trial in greater detail.

Results

Out of 2,054 clinical drug trials, 196 (9.5%) were undertaken in general practice; 93% were multinational, 96% were industry funded and 77% included patients both from general practice and specialist care. The trials were planned to be completed in the period 1998 to 2012. A total of 23,000 patients in Norway and 340,000 patients internationally were planned to be included in the 196 trials. A median of 5 GPs participated in each trial (range 1 to 402). Only 0.7% of 831 GP investigators had general practice university affiliations. Median payment for participating investigators was €1,900 (range €0 to 13,500) per patient completing the trial. A total of 30 pharmaceutical companies were involved. The drugs most commonly studied were antidiabetics (21%), obstructive airway disease medications (12%), agents acting on the renin-angiotensin system (10%), and lipid modifying agents (10%). One trial, presented in more detail, had several characteristics of a seeding or marketing trial.

Conclusions

Only one in four drug trials involving general practice were solely general practice trials and almost all were industry initiated without input from academic general practice. There was a large variation in the number of patients, participating doctors, and economic compensation for trial investigators, with some investigators receiving substantial payments.

Keywords

  • Clinical trial
  • Drug industry
  • General practice
  • Patient selection
  • Randomized controlled trials

Background

About 90% of all drug prescriptions for outpatients are issued in general practice [1]. Patients in general practice are more likely to have less severe disease, and more undifferentiated symptoms than selected patients in secondary or tertiary health care, however, multimorbidity is common [2]. If a study population in a drug trial differs significantly from the population where the drug is most likely to be prescribed, the external validity of the trial may be impaired [3]. To avoid this uncertainty, many have argued that more clinical drug trials should be conducted in primary care settings to ensure that the benefits are proportionate to the risks and costs of the treatment for patients in general practice [4, 5]. Clinical drug trials may serve different purposes, from research of effectiveness, to marketing [6]. Trials with the main purpose of introducing new drugs to prescribers are often referred to as ‘seeding trials’. Various criteria for seeding trials have been proposed (Table 1) [79], and it is characteristic that the trials are designed to make many clinicians familiar with a new drug. Being frequent prescribers, general practitioners (GPs) are probably of particular interest for designers of seeding trials; this is also because GPs are relatively independent in their decision-making processes.
Table 1

Case study: the ‘On-demand Nexium Evaluation’ (ONE) trial a

Key characteristics of seeding trials[79]

Does this apply for the ONE trial?

Tests a new drug recently or about to be licensed

Yes: application year 2000, study completed by the end of 2001; esomeprazole licensed in 2001

Many well established competing products

Yes: omeprazole from 1989, lansoprazole and pantoprazole from 1995

Many patients included

Yes: 2,500 patients (the trial with most Norwegian patients to be included). In addition, similar studies have been conducted in other countries (see main text).

Frequent prescribers in the role of clinical investigators

Yes: 402 general practitioners (GPs; the study involving most Norwegian GP investigators)

Often redundant as they are not designed for answering a scientific problem

Probably yes

Unreasonably high payments for the investigators

No: €750 which is below the 25th percentile for all trials

Results are often not published

No: there were three publications

Conducted by drug company marketing departments

Unknown

aFull trial title: ‘Long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) comparing costs and efficacy over six months of treatment with esomeprazole 20 mg q.d on demand treatment or esomeprazole 20 mg q.d continuous treatment or ranitidine 150 mg b.i.d. continuous treatment. An open, randomised, multicenter study. On-demand Nexium Evaluation - ONE’. Sponsor: AstraZeneca.

In the UK between 1984 and 1989, general practice trials initiated by pharmaceutical companies were judged to have a low output of clinically relevant results [10]. The concerns addressed in that audit were mainly payments to GPs, information and safety issues, shortfall of investigators and patients, leading to inconclusive results, and low publication rates [10]. Among general practice studies published 1991 to 1996 in the BMJ, the British Journal of General Practice, and Family Practice, only 6% were randomized controlled trials, which was pointed out as a major challenge for the general practice research community [11]. Some Norwegian data regarding clinical drug trials have previously been reported, based on research applications submitted to the Research Ethical Committees (REC) [1214] and the Norwegian Medicines Agency (NoMA) [15, 16]. Between 68% and 85% of the trials were initiated by pharmaceutical industry [1315], however, neither of these reports highlighted studies in general practice.

From the 1970s, a subcommittee of the Norwegian College of General Practitioners had a voluntary agreement with the pharmaceutical industry to assess protocols for studies to be performed in general practice [17, 18]. If the committee judged the trial to be clinically relevant and of sound scientific quality, GPs were recommended to participate in the trial. However, by the turn of the millennium, the committee voiced critical comments regarding some trials judged to be marketing (due to features of seeding trials) rather than research [17]. Since then, this voluntary quality and relevance check has been largely bypassed by the industry [19], and information regarding industry initiated research in Norwegian general practice has thus become an almost hidden reality except for the investigators themselves. This prompted the Norwegian College of General Practitioners in 2008 to fund research to gain systematic knowledge of the drug research carried out by GPs. This included establishing an overview of all trials conducted, exploring whether GPs were subject for marketing trials, and assessing the relevance of the research questions addressed, as well as the studies’ validity and publication output. The College requested this knowledge due to possible implications for their policy for future professional development within the discipline of general practice.

The aim of the present study was to establish a descriptive basis regarding clinical drug trials conducted in general practice by research areas and trial characteristics. As most clinical drug trials are multinational, this study also should concern research in general practice outside of Norway.

Methods

In Norway, the only complete national archive for drug trials is held by NoMA. Based on a hand search of the NoMA archive for the 10-year period 1998 to 2007, we describe all clinical trials planned to be carried out in general practice by their funding, clinical setting, drugs, diagnoses, patients, clinical investigators and economic compensations for the investigators. More detail will be given regarding one of the trials in year 2000, which the Norwegian College of GPs discouraged GPs to join [17], to give the reader a better sense of what we consider a seeding trial. Ethical approval for our study was not required.

Dataset

In Norway, all clinical pharmaceutical trials regardless of setting need approval from NoMA, the national, regulatory authority for new and existing medicines. Clinical trials are regulated by international and national laws, in which there were amendments between 1998 and 2007, and from 2004 the European Directive 2001/20/EC has been implemented in the Norwegian regulation [16]. By hand searching NoMA’s total paper archive, protocol by protocol, we were able to identify application forms, protocols and other correspondence received by NoMA regarding applications for clinical drug trials between 1998 and 2007, the 10-year period before conversion to electronic registration. The computed total number of trial applications during this decade was 2,054 [16, 20] (personal communication from I. Aaløkken, NoMA). The main hand search was performed in May to August 2008 by KBJ. Supplementary data collection and verification was performed by AMB between November to December 2011 for a total of 89 studies. No formal inter-rater reliability calculations were performed, but no significant errors or discrepancies were disclosed. A random check of non-included studies in the archive did not reveal any additional general practice trials. Applications for trials planned to take place solely or partly in general practice were included. General practice trials were defined as trials where the address and/or titles indicated that at least one of the Norwegian clinical investigators worked in general practice.

Variables: trial characteristics

For included studies, we recorded study title, medication tested in terms of its Anatomical Therapeutic Chemical (ATC) classification code [21], funders, whether the study was planned exclusively to be conducted in general practice or also in specialist care settings, whether it was a national or international study, and trial phase based on explicit information in the application ((I) study of toxicity and side effects; (II) study of dose-response; (III) comparison with established treatment or placebo; or (IV) post-marketing study, gaining broader experience) [6]. We defined a study as industry initiated when a pharmaceutical company funded the study, wrote the study protocol or conducted the study, either the company itself or via a contract research organization. If the study drugs were provided free of charge, but the trial was otherwise designed and conducted independently under the responsibility of a GP researcher, it was defined as researcher initiated. There were no trials with unclear funding. We recorded the number of patients planned to be included internationally, and at Norwegian trial sites, the number of clinical investigators involved, trial duration, and if available, economic compensation for physicians involved. We also identified clinical investigators who were GP academics, that is, having affiliations to Norwegian general practice university departments. The main diagnostic criteria for inclusion in a study were based on the study title, and when necessary supplemented with information from the protocol and categorized according to the International Classification of Primary Care, second edition (ICPC-2) [22]. One of the authors (AMB) performed the categorization, and when in doubt, consensus was reached through discussions between AK, JS and AMB.

Data analysis

Data were compiled in a spreadsheet. To compare planned number of patients to be enrolled in trials partly or entirely to be undertaken in general practice, we used the independent samples Mann-Whitney U test, and otherwise we used descriptive statistics. Due to data skewness, median values are presented rather than means. We roughly estimated investigator incomes by multiplying median payment and median number of patients planned recruited divided by median number of investigators. Statistical analyses were performed using SPSS statistics (PASW Statistics 18; SPSS Inc., Chicago, IL, USA).

Case study

One outlying case is described in greater detail. For this trial, additional information is given on patients, interventions, comparison and outcome based on the study protocol. A systematic literature search was performed to identify publications arising from the trial (date of literature search, 17 September 2012). The trial was assessed according to the proposed criteria for seeding trials outlined in Table 1[79].

Results

Dataset: general practice drug trials

During the 10-year period of applications, a total of 196 studies (9.5% of all 2,054 clinical drug trials) were planned to be conducted entirely or partly in a general practice setting. Of these, 189 (96.4%) trials were industry initiated and 7 (3.6%) were researcher initiated (Table 2). The trials were planned to be completed in the period 1998 to 2012. Figure 1 shows that the majority of the 196 trials had trial sites both in general practice and in specialist care. The majority of the trials were multinational. Only 45 trials (2.2% of all) were planned conducted entirely in general practice. The number of participating countries per trial varied from 1 to 50 (median: 9, interquartile range 5 to 17); however, for 112 trials information regarding the number of countries was incompletely stated.
Table 2

Clinical drug trial applications in Norway 1998 to 2007

Year

General practice trials

All clinical trials

 

Industry initiated (GP only)

Researcher initiateda

Total (GP only)

Industry initiated

Researcher initiated

Total

1998

17 (7)

0

17 (7)

186

50

236b

1999

16 (6)

0

16 (6)

161

28

189c

2000

23 (10)

1

24 (11)

173

65

238d

2001

22 (1)

0

22 (1)

158

62

220d

2002

16 (5)

2

18 (7)

143

50

193d

2003

14 (1)

1

15 (2)

151

50

201d

2004

22 (2)

1

23 (3)

171

60

231d

2005

18 (2)

1

19 (3)

139

55

194d

2006

20 (1)

1

21 (2)

113

60

173d

2007

21 (3)

0

21 (3)

126

53

179d

Total

189 (38)

7

196 (45)

1,521

533

2,054

Mean/year

18.9 (3.8)

0.7

19.6 (4.5)

152.1

53.3

205.4

Applications at the Norwegian Medicines Agency (NoMA) for clinical drug trials conducted entirely (general practitioners (GPs) only) or partly in general practice identified by hand searching of all the clinical trials in the archive. For comparison, an overview of all clinical trials is included.

aAll researcher-initiated trials were GP only.

bPersonal communication from Ingvild Aaløkken, Head of section, Preclinical assessment and clinical trials, NoMA, 2008.

cSee [16].

dSee [20].

Figure 1
Figure 1

General practice clinical drug trials in Norway 1998 to 2007. Applications to the Norwegian Medicines Agency (NoMA) for industry initiated or researcher initiated clinical drug trials conducted entirely or partly in general practice as identified by hand search of the clinical trials archive. A total number of 2,054 clinical drug trials during the time period was calculated (personal communication from Ingvild Aaløkken, Head of section, Preclinical assessment and clinical trials, NoMA, 2008; see also [16, 20]).

Trial characteristics

A total of 30 different pharmaceutical companies applied for drug trials in general practice during this 10-year period. The initiators (number of trials) were GlaxoSmithKline (39), AstraZeneca (32), Novartis (21), MSD (19), Pfizer (11), Novo Nordisk (9), Boehringer Ingelheim (8), Roche (7), Lundbeck (5), and Schering-Plough (4). In addition, 5 companies initiated 3 trials, 4 companies initiated 2 trials, and 11 companies initiated 1 trial. The top 5 companies in terms of Norwegian market share [23] were responsible for 107 (55%) of all trials.

Table 3 shows the number of patients and physicians involved and estimated economic compensation for the investigators. More than 23,000 Norwegian patients were to be included in the 196 trials, and almost 340,000 patients included internationally. In 6 trials the planned number of included patients was more than 10,000, and in 10 trials the number was less than 100 patients. The recruitment targets did not differ between trials in general practice only and those undertaken in mixed health care settings (P = 0.91). Only 6 (0.7%) out of 831 clinical investigators were general practice academics, 3 of whom were only involved in trials without commercial sponsors. Information regarding trial investigators’ payment was missing in 90 applications, 73 of which were from the period 1998 to 2002.
Table 3

Characteristics for clinical drug trials in general practice

 

Patients planned for inclusion

Clinical investigators

Payment

 

Norway

All countries

Trial duration, weeks

General practicea

All sites in Norway

Investigators' payment per patient, €b

Estimated yearly income per investigator, €c

Median

60

672.5

24

5

7

1,900

1,600

Minimum to maximum

8 to 2,500

8 to 31,000

1 to 288

1 to 402

1 to 402

0 to 13,500

0 to 59,000

2.5 to 97.5 percentile

13 to 560

50 to 14,368

3 to 240

1 to 37

1 to 61

0 to 7,500

0 to 25,000

Sum

23,635

337,921

 

1,920

2,475

  

This table shows trial characteristics of applications at the Norwegian Medicines Agency (NoMA), 1998 to 2007, for 196 clinical drug trials conducted solely or partly in general practice identified by hand searching of the archive.

aGeneral practitioners (GPs) participated in clinical trials from 1 to 36 times, with median 1 and interquartile range 1 to 2. A total of 831 unique GPs participated.

bInformation missing in 90 applications.

cCalculated using median payment and median number of patients recruited per investigator. This payment covers all expenses connected with the trial for the investigator.

We were able to record the study phase in 122 trials, out of which none were phase I studies, 11% were phase II studies, 61% phase III and 27% phase IV studies.

Drugs from 30 different therapeutic groups were investigated in the trials (Table 4). The largest groups were antidiabetics, drugs for obstructive airway diseases, agents acting on the renin-angiotensin system, and lipid modifying agents. The top 5 therapeutic subgroups represented 121 (59%) of all drug groups tested, the top 10 represented 158 (78%). Only one of the trials investigated medication discontinuation.
Table 4

Anatomical Therapeutic Chemical classification (ATC code a ) for test drugs in clinical drug trials in general practice

Anatomical main ATC group

n

%

Therapeutic ATC subgroup

n

%

Rank (1 to 10)

A: Alimentary tract and metabolism

52

25.5

A02: Drugs for acid-related disordersb

7

3.4

7

   

A03: Drugs for functional gastrointestinal disorders

2

1.0

 
   

A08: Antiobesity preparations, excluding diet products

1

0.5

 
   

A10: Drugs used in diabetesb

42

20.6

1

B: Blood and blood-forming organs

4

2.0

B01: Antithrombotic agents

4

2.0

 

C: Cardiovascular system

46

22.5

C02: Antihypertensives

2

1.0

 
   

C08: Calcium channel blockersb

2

1.0

 
   

C09: Agents acting on the renin-angiotensin system

21

10.3

3

   

C10: Lipid modifying agentsb

21

10.3

3

D: Dermatologicals

2

1.0

D01: Antifungals for dermatological use

1

0.5

 
   

D04: Antipruritics, including antihistamines, anesthetics, etc.

1

0.5

 

G: Genitourinary system and sex hormones

8

3.9

G02: Other gynecologicals

1

0.5

 
   

G03: Sex hormones and modulators of the genital system

2

1.0

 
   

G04: Urologicals

5

2.5

10

H: Systemic hormonal preparations

3

1.5

H02: Corticosteroids for systemic usec

2

1.0

 
   

H05: Calcium homeostasis

1

0.5

 

J: Anti-infectives for systemic use

22

10.8

J01: Antibacterials for systemic useb

4

2.0

 
   

J05: Antivirals for systemic use

12

5.9

6

   

J07: Vaccines

6

2.9

9

L: Antineoplastic and immunomodulating agents

2

1.0

L01: Antineoplastic agents

2

1.0

 

M: Musculoskeletal system

15

7.4

M01: Anti-inflammatory and antirheumatic products

13

6.4

5

   

M05: Drugs for treatment of bone diseases

2

1.0

 

N: Nervous system

23

11.3

N02: Analgesics

7

3.4

7

   

N04: Anti-Parkinson drugs

2

1.0

 
   

N05: Psycholepticsc

5

2.5

 
   

N06: Psychoanalepticsc

5

2.5

 
   

N07: Other nervous system drugs

4

2.0

 

R: Respiratory system

26

12.7

R01: Nasal preparations

1

0.5

 
   

R03: Drugs for obstructive airway diseasesc

24

11.8

2

   

R06: Antihistamines for systemic use

1

0.5

 

Missing information

   

1

0.5

 

Total number of ATC codes

   

204

100

 

This table shows the ATC codes of drug being tested identified from applications to the Norwegian Medicines Agency (NoMA) for 196 clinical drug trials between 1998 and 2007 conducted entirely or partly in general practice through hand searching the archive.

aSee [21].

bAdditional ATC code in a total of eight trials with two ATC codes registered.

cATC code in researcher-initiated trials; for the groups H02, N05 and R03 there were two trials.

The main diagnostic inclusion criteria represented 44 different diagnoses (Table 5), the top 5 of which made up 114 (52% of the inclusion criteria) and the top 10 made up 146 (67%). In 14 trials no diagnosis was applicable, that is, healthy people, subjects over a certain age, smokers, and patients using baby aspirin.
Table 5

Main diagnostic criteria for inclusion classified in terms of International Classification of Primary Care (ICPC) diagnoses a for clinical drug trials

ICPC diagnosis

n

%

GP only

T90: Diabetes, non-insulin dependent

44

20.2

1

K86: Hypertension, uncomplicated

22

10.1

7

R96: Asthma

19

8.7

4

T93: Lipid disorder

18

8.3

2

R80: Influenza

11

5.0

7

L89: Osteoarthrosis of hip

7

3.2

2

L90: Osteoarthrosis of knee

7

3.2

3

N89: Migraine

7

3.2

1

R95: Chronic obstructive pulmonary disease

6

2.8

2

P76: Depressive disorder

5

2.3

2

K78: Atrial fibrillation/flutter

4

1.8

 

L88: Rheumatoid/seropositive arthritis

4

1.8

 

T82: Obesity

4

1.8

 

D07: Dyspepsia/indigestion

3

1.4

2

P70: Dementia

3

1.4

2

T99: Endocrine/metabolic/nutritional disease, other

3

1.4

 

D84: Oesophagus disease

2

0.9

2

D93: Irritable bowel syndrome

2

0.9

1

L84: Back syndrome without radiating pain

2

0.9

1

L91: Osteoarthrosis, other

2

0.9

1

L95: Osteoporosis

2

0.9

 

N04: Restless legs

2

0.9

 

P06: Sleep disturbance

2

0.9

 

R78: Acute bronchitis/bronchiolitis

2

0.9

2

U04: Incontinence, urine

2

0.9

 

Y07: Impotence, not otherwise specified

2

0.9

 

A23: Risk factor, not otherwise specified

1

0.5

1

A91: Abnormal result investigation, not otherwise specified

1

0.5

 

D12: Constipation

1

0.5

 

K76: Ischemic heart disease without angina

1

0.5

 

K99: Cardiovascular disease, other

1

0.5

 

L29: Symptom/complaint, musculoskeletal, other

1

0.5

 

L92: Shoulder syndrome

1

0.5

1

L93: Tennis elbow

1

0.5

1

L99: Musculoskeletal disease, other

1

0.5

 

R28: Limited function/disability (respiratory)

1

0.5

 

R75: Sinusitis, acute/chronic

1

0.5

1

R76: Tonsillitis, acute

1

0.5

1

R81: Pneumonia

1

0.5

 

R97: Allergic rhinitis

1

0.5

 

S74: Dermatophytosis

1

0.5

1

T89: Diabetes, insulin dependent

1

0.5

 

X11: Menopausal symptom/complaint

1

0.5

 

No diagnosis applicable

14

6.4

2

Totalb

218

100

 

Table shows main inclusion criteria classified as ICPC diagnoses identified from applications at the Norwegian Medicines Agency (NoMA) for 196 clinical drug trials between 1998 to 2007 conducted entirely (general practitioner (GP) only) or partly in general practice through hand searching of the archive.

aSee [22].

bA total of 22 studies had 2 or more diagnoses as inclusion criteria; 3 studies had 3 diagnoses.

Case study

In Table 1, more detail is given for one particular trial which the Norwegian College of GPs discouraged GPs to join [17], the ‘On-demand Nexium Evaluation’ trial, with the following clinical characteristics. Patients: patients with symptoms suggestive of gastroesophageal reflux disease (GERD; heartburn with or without acid regurgitation) for 3 days or more were included. Only patients with effect of treatment with esomeprazole 40 mg were randomized for comparison with ranitidine. Intervention: the drug tested was esomeprazole 40/20 mg daily. Comparison: there was initially no comparison; if treatment success in the run-in period with esomeprazole 40 mg daily, comparison was esomeprazole 20 mg daily on demand or ranitidine 150 mg twice daily. Outcomes: difference in direct medical costs (mean per patient) was the primary outcome, secondary objectives included health care contacts, tests and procedures, hospitalizations, patient time and travel costs, early retirement, absence from work, symptom registration, quality of life, self-perceived overall treatment effect, and patient satisfaction. Among all 196 trials in Norwegian general practice during the decade, this trial was designed to include the largest number of national GP investigators and patients. In the sample size calculations a power of 95% (beta = 0.05) was used. The significance level alpha was 5%. The study had an open design, with no blinding. There was a run-in period before randomization, and only patients responding to the high dose esomeprazole treatment were randomized and included in the intention-to-treat analyses. Per protocol analyses were also used. Three journal articles presenting results from the study were identified [2426].

Discussion

The main findings in this study were that only about one-tenth of all clinical drug trials in Norway involved GPs as clinical investigators recruiting patients from their practices, and only 3.6% of these were non-industry trials.

We found that the proportion of researcher-initiated clinical drug trials in general practice in Norway was minute (3.6%) compared to clinical drug trials from other fields of medicine where 15% to 32% are non-commercial studies [1315]. Conducting clinical trials in general practice poses some typical challenges, like difficulties with study logistics and patient recruitment in a large number of small trial sites [4]. The lack of researcher-initiated trials has also been pointed out in the European Research Agenda for General Practice [5]. Irrespective of their commercial interests, this research agenda underlines that drugs mainly targeting primary care should be appropriately tested in primary care settings. Furthermore, that a stable funding and formation of research networks may facilitate non-commercial randomized controlled trials in general practice [5]. Although many have pointed to the need for clinical drug trials conducted independently of the industry, there was nonetheless a decline in the number of non-commercial randomized controlled trials in the UK between 1980 and 2002 [27]. Several systematic reviews have pointed out that drug trials financed by pharmaceutical industry tend to publish results more in favor of the manufacturer’s product than non-commercial trials, and that negative studies in this respect commonly remain unpublished [2832]. This publication bias combined with the lack of non-industry trials in general practice might therefore contribute to an evidence-biased knowledge base.

Over the last few years, there has been a decline in the number of clinical trials in several European countries [33, 34]. In Norway, the largest reduction has been in phase III studies [16]. For general practice studies we were not able to confirm this trend, even if the majority of trials in our material were phase III or IV. The trials where explicit information regarding trial phase was missing, were most likely also phase III or IV. The five companies funding most general practice trials were among the seven most profitable companies, thus largely reflecting their market positions [23].

A study from 2000 found that 84% of GPs in a part of England had been involved in research, 48% mainly in clinical trials [35]. Our figures indicate that Norwegian GPs’ participation rate in clinical trials is less than half of that in the UK; the 831 GPs involved correspond to about 20% of all Norwegian GPs in 2002 [1]. Surprisingly few GPs with university affiliations had participated in clinical drug trials, although many of them work part-time as GPs and are particularly interested in clinical research. Explanations for this finding may be that they judged the clinical relevance of the industry funded trials to be low, feared conflicts of interest, or had general negative attitudes towards collaboration with pharmaceutical companies [36]. Most GPs involved in clinical trials only participated once or just a few times, and did therefore not gain large incomes for participating. However, a number of GPs were involved in quite a few trials, giving them a substantial yearly income from trial participation. A few trials also gave outstandingly high payment for the doctors involved. Most GPs in Norway are self-employed with a major part of their income from patient payment and per capita reimbursement. It is therefore reasonable that extra workload due to participation in clinical trials is compensated. But how much is a reasonable level of compensation? Payment to clinicians for participation in clinical trials varies a lot [36, 37]. Andersen et al. report payments of US $800 per patient enrolled for a Danish industry initiated trial [37], which is approximately one-third of the median payment in our material. Raftery et al. point to the striking lack of transparency in guidelines for payments for involvement in research, where GPs are among the few individual clinicians where direct personal payment still is common [36]. Concerns have been voiced that high payments may create conflicts of interest and possibly lead to unethical recruitment processes [36]. This demands rigorous ethical standards from both the general practice community and the pharmaceutical industry.

We identified antidiabetic drugs and type II diabetes to be studied most frequently. Thomas et al. found few published articles on diabetes in UK primary care journals in the 1990s [11]. The general use of antidiabetics in Norway increased by 27% (in defined daily doses (DDDs)) from 2004 to 2008 [38]. This may both reflect increasing diabetes prevalence but also the introduction of new drugs. Andersen et al. found that physicians conducting a clinical trial, significantly increased the sponsor’s share of prescribed drugs for the disease compared to GPs not involved in the trials [37], and this might be important for expanding the market. The many post-marketing studies of new and expensive insulin analogues with large market potentials have recently been criticized for limited scientific value [9]. The three largest drug groups investigated in our study were among the four most consumed drugs in Norway (in terms of DDDs) [38]. These therapeutic areas were also among the six most frequently researched topics in general practice internationally between 2003 and 2008 [5]. In Norway in years 2000 and 2004 [14], and in the UK 1980 to 2002 [27], most clinical trials were in the field of cancer and antineoplastic and immunomodulating drugs. We only identified two trials in this field. This was as expected, as GPs rarely initiate antineoplastic drug prescriptions. Only one trial studied the effects of discontinuation of (unnecessary) medication use, although this is an important topic both for quality of care and general practice research [5].

Strengths and limitations of the study

The NoMA archive is a mandatory, complete national archive of all clinical drug trials in Norway, and it is a strength that we managed to include all trial protocols, not restricted to a specific region or to trials that had been reported in scientific publications. The large proportion of multinational trials identified also increases the external validity of our findings, which therefore may be relevant for general practice in other countries. As the identification of trials was performed by hand searching, random errors may have occurred during this process and recording of results. The main hand search was performed by only one of the authors, but supplementary searches in the archive for completing information by another author did not reveal significant errors. The total number of trials (2,054 trials) for the 10-year period was summed up from numbers provided by NoMA, and the exact total number of investigated paper files was not recorded, although the whole archive was searched shelf by shelf. Some uncertainty regarding missing files in the archive is therefore possible, however, we believe the number of missing files to be negligible due to strict control and restricted access to the state run archive. We have not addressed the number of clinical trials that were never conducted, either from lack of approval from REC or NoMA, or for other reasons, but this will be a subject of future research. The patient numbers reported involve all trial sites in Norway, and we do not know the exact number of general practice patients. Concerning trial phase, the proportion of missing data was quite large. The same applies to investigator payments, which were under-reported to NoMA, especially during the first years in the time period studied.

Case study: a seeding trial?

The intentions for conducting a seeding trial are in general hidden and they may therefore be difficult to identify. Seeding trials have usually been disclosed based on documents from litigation processes [39, 40]. Without access to internal communication within the drug company, the judgment of whether a trial is designed for marketing has to be based on several aspects. The esomeprazole trial described has many features being typical for a seeding trial, with several of the key characteristics described in Table 1[79].

Esomeprazole was launched in 2001 in a crowded drug group. It is the most expensive of the proton pump inhibitors, and had become the tenth most-sold medicine in Norway in 2008 calculated in terms of pharmacy retail prices [38]. The esomeprazole trial described was large, and the sample size calculations were based on a higher power than conventionally used [41]. A higher power demands larger sample sizes and more patients to be enrolled into the study. No ethical considerations regarding these issues were discussed in the peer-reviewed publications arising from the trial [2426]. The open design and the inclusion only of patients responding to high doses of esomeprazole in the intention-to-treat analyses increased the risk of bias in favor of esomeprazole. One may question the scientific need for recruiting around 400 GPs in the trial, each GP only enrolling a handful of patients with gastroesophageal reflux, a relatively common health complaint. The large number of participating doctors was not explained or justified in the protocol or in publications arising from the trial [2426]. Nevertheless, the trial was approved by both the regional ethics committee and NoMA without any major remarks. The general practice research committee criticized this protocol on several issues, some of which are listed above [17, 19, 42]. The trial was presented in Norway as a separate trial, but quite similar studies with the same protocol acronym (ONE) have been reported from Denmark (without ranitidine comparison) [43] and Switzerland [44] in total involving almost 3,500 patients.

Conclusions

Only one-tenth of all clinical drug trials in Norway involved patients recruited from general practice, and just one in four of these trials were solely general practice trials. Almost all trials were industry initiated without input from academic general practice. This shows that it is a challenge for general practice to increase the number of clinical trials in general and researcher initiated clinical drug trials in particular. Antidiabetic drugs were most commonly studied. There was a large variation in the number of patients, participating doctors, and economic compensation for trial investigators, with some investigators receiving substantial payments. We describe a study with several characteristics of a seeding trial, where none of the official approving bodies for clinical trials had any major remarks. It raises the important ethical considerations with regard to exposing patients to unnecessary risks in either an inordinately large or a small, underpowered trial.

In this descriptive study, we have addressed neither the relevance of the research questions for general practice nor the methodological quality or publication output of the trials beyond the case study. These are important issues that we intend to explore in forthcoming research.

Abbreviations

ATC code: 

Anatomical Therapeutic Chemical classification code

DDD: 

Defined daily dose

ICPC: 

International Classification of Primary Care

GP: 

General practitioner

NoMA: 

Norwegian Medical Agency.

Declarations

Acknowledgements

We thank Ingvild Aaløkken, Head of Section, for preclinical assessment and clinical trials at the Norwegian Medicines Agency for positive support, guidance and admission to the NoMA archive. We also thank Rune B Jakobsen for critically reviewing the manuscript. This study was funded by a research scholarship from The General Practice Research Fund from The Norwegian Medical Association.

Authors’ Affiliations

(1)
Department of General Practice, Institute of Health and Society, Faculty of Medicine, University of Oslo, PO Box 1130, Blindern, Oslo, N-0318, Norway

References

  1. Hunskår S: Allmennmedisin [General Practice]. 2003, Oslo, Norway: Gyldendal Norsk Forlag, 2Google Scholar
  2. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012, 380: 37-43.View ArticlePubMedGoogle Scholar
  3. Rothwell PM: External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005, 365: 82-93.View ArticlePubMedGoogle Scholar
  4. Gagyor I, Bleidorn J, Wegscheider K, Hummers-Pradier E, Kochen MM: Practices, patients and (im)perfect data - feasibility of a randomised controlled clinical drug trial in German general practices. Trials. 2011, 12: 91-View ArticlePubMedPubMed CentralGoogle Scholar
  5. Hummers-Pradier E, Beyer M, Chevallier P, Eilat-Tsanani S, Lionis C, Peremans L, Petek D, Rurik I, Soler JK, Stoffers HE, Topsever P, Ungan M, van Royen P: Series: The research agenda for general practice/family medicine and primary health care in Europe. Part 4. Results: specific problem solving skills. Eur J Gen Pract. 2010, 16: 174-181.View ArticlePubMedGoogle Scholar
  6. Laake P, Benestad HB, Olsen BR: Research Methodology in the Medical and Biological Sciences. 2007, London, UK: Academic PressGoogle Scholar
  7. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP: Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med. 1994, 331: 1350-1353.View ArticlePubMedGoogle Scholar
  8. Ross JS, Gross CP, Krumholz HM: Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health. 2012, 102: 72-80.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Gale EA: Post-marketing studies of new insulins: sales or science?. BMJ. 2012, 344: e3974-View ArticlePubMedGoogle Scholar
  10. Wise P, Drury M: Pharmaceutical trials in general practice: the first 100 protocols. An audit by the clinical research ethics committee of the Royal College of General Practitioners. BMJ. 1996, 313: 1245-1248.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Thomas T, Fahey T, Somerset M: The content and methodology of research papers published in three United Kingdom primary care journals. Br J Gen Pract. 1998, 48: 1229-1232.PubMedPubMed CentralGoogle Scholar
  12. Winther FO, Hole OP: Scientific quality of clinical research. An analysis of 40 research projects in pharmacology/pharmacotherapy. Eur J Clin Pharmacol. 1997, 51: 351-354.View ArticlePubMedGoogle Scholar
  13. Hole OP, Winther FO, Straume B: Clinical research: the influence of the pharmaceutical industry. Eur J Clin Pharmacol. 2001, 56: 851-853.View ArticlePubMedGoogle Scholar
  14. Winther FO, Hole OP, Nitter-Hauge S: An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry. Eur J Clin Pharmacol. 2007, 63: 909-912.View ArticlePubMedGoogle Scholar
  15. Sandaker L, Fjeld B, Reikvam A, Lislevand H, Madsen S: [Clinical trials in Norway - completion and reporting are not satisfactory]. Tidsskr Nor Laegeforen. 2004, 124: 2888-2890.PubMedGoogle Scholar
  16. Bjørnhaug E, Aaløkken I: [Clinical trials in Norway the last 10 years]. Nor Farm Tidsskr. 2010, 12: 12-14.Google Scholar
  17. Holtedahl KA, Meland E, Klovning A: [Critical questions to drug industry]. Tidsskr Nor Laegeforen. 2001, 121: 1403-1404.Google Scholar
  18. Meland E: Research ethics - revisited. Scand J Prim Health Care. 2003, 21: 129-131.View ArticlePubMedGoogle Scholar
  19. Holtedahl KA, Meland E: Drug trials in general practice: time for a quality check before recruiting patients. BMJ. 2007, 335: 7-View ArticlePubMedPubMed CentralGoogle Scholar
  20. Norwegian Medicines Agency: [Yearly report. 2008, [http://slv.no/Om_Legemiddelverket/arsrapportar/Documents/aarsrapport_legemiddelverket_2008_web_090604.pdf], ]Google Scholar
  21. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index. [http://www.whocc.no/atc_ddd_index/]
  22. ICPC: International Classification of Primary Care 2nd edition, electronic version. [http://www.kith.no/upload/2705/ICPC-2-English.pdf]
  23. The Pharmaceutical Industry in Norway: Facts and Figures. 2008, [http://www.lmi.no/english]
  24. Hansen AN, Bergheim R, Fagertun H, Lund H, Moum B: A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms og gastroesophageal reflux disease. Int J Clin Pract. 2005, 59: 665-671.View ArticleGoogle Scholar
  25. Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B: Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006, 60: 15-22.View ArticlePubMedGoogle Scholar
  26. Hansen AN, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, Moum B: Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract. 2005, 59: 655-664.View ArticlePubMedGoogle Scholar
  27. Chalmers I, Rounding C, Lock K: Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980–2002. BMJ. 2003, 327: 1017-View ArticlePubMedPubMed CentralGoogle Scholar
  28. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L: Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012, 12: MR000033-PubMedGoogle Scholar
  29. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD: The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int. 2010, 107: 295-301.PubMedPubMed CentralGoogle Scholar
  30. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003, 289: 454-465.View ArticlePubMedGoogle Scholar
  31. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003, 326: 1167-1170.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Sismondo S: Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008, 29: 109-113.View ArticlePubMedGoogle Scholar
  33. Hartmann M: Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Trials. 2012, 13: 53-View ArticlePubMedPubMed CentralGoogle Scholar
  34. Berendt L, Hakansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE: Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993–2006. BMJ. 2008, 336: 33-35.View ArticlePubMedGoogle Scholar
  35. Jowett SM, Macleod J, Wilson S, Hobbs FD: Research in primary care: extent of involvement and perceived determinants among practitioners from one English region. Br J Gen Pract. 2000, 50: 387-389.PubMedPubMed CentralGoogle Scholar
  36. Raftery J, Bryant J, Powell J, Kerr C, Hawker S: Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study. Health Technol Assess. 2008, 12: 10-View ArticleGoogle Scholar
  37. Andersen M, Kragstrup J, Sondergaard J: How conducting a clinical trial affects physicians' guideline adherence and drug preferences. JAMA. 2006, 295: 2759-2764.View ArticlePubMedGoogle Scholar
  38. Nordic Medico-Statistical Committee/Nordic Social Statistical Committee: Medicines Consumption in the Nordic Countries. 2004, [http://www.nom-nos.dk], -2008Google Scholar
  39. Krumholz SD, Egilman DS, Ross JS: Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. Arch Intern Med. 2011, 171: 1100-1107.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Hill KP, Ross JS, Egilman DS, Krumholz HM: The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008, 149: 251-258.View ArticlePubMedGoogle Scholar
  41. Altman DG: Practical Statistics for Medical Research. 1991, London, UK: Chapman & HallGoogle Scholar
  42. Holtedahl KA, Meland E, Klovning A: [New critical questions to drug industry]. Tidsskr Nor Laegeforen. 2002, 122: 2309-PubMedGoogle Scholar
  43. Meineche-Schmidt V, Juhl HH, Ostergaard JE, Luckow A, Hvenegaard A: Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther. 2004, 19: 907-915.View ArticlePubMedGoogle Scholar
  44. Beglinger C, Thalmann C, Szucs T, Michetti P: [Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 months of treatment with Nexium On-Demand Treatment or Nexium continuous treatment. An open, randomised multi-center study]. Praxis (Bern 1994). 2006, 95: 483-487.View ArticleGoogle Scholar

Copyright

© Brænd et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement